IO Biotech Announces Participation in Upcoming Investor Conferences
September 06 2023 - 8:35AM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® technology platform, today announced its
participation in the upcoming investor conferences:
Event: Morgan Stanley 21st Annual Global
Healthcare ConferenceLocation: New York, New YorkFireside Chat Date
& Time: Tuesday, September 12, 2023 at 4:15 pm ETPresenter:
Mai-Britt Zocca, PhD, CEOWebcast Link: Here
Event: H.C. Wainwright 25th Annual Global
Investment ConferenceLocation: New York, New YorkPresentation Time:
Wednesday, September 13, 2023 at 2:00 pm ETPresenter: Mai-Britt
Zocca, PhD, CEOWebcast Link: Here
A webcast replay of the presentations will be
available on IO Biotech’s website at www.iobiotech.com for 90
days following the presentation.
About IO102-IO103
IO102-IO103 is an investigational
immune-modulating cancer vaccine designed to target the
immunosuppressive mechanisms mediated by the proteins indoleamine
2,3-dioxygenase (IDO) and PD-L1. The company is currently
conducting a Phase 3 trial (IOB-013/KN-D18; NCT05155254) evaluating
IO102-IO103 in combination with pembrolizumab in first-line
advanced melanoma patients, and a Phase 2 basket trial
(IOB-022/KN-D38; NCT05077709) evaluating IO102-IO103 in combination
with pembrolizumab in first-line advanced non-small lung cancer and
head and neck cancer.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® vaccine platform. The T-win platform is a novel
approach to cancer vaccines designed to activate T cells to target
the most important immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing in clinical studies its
lead cancer vaccine candidate, IO102-IO103, targeting IDO and
PD-L1, and through preclinical development its other pipeline
candidates. IO Biotech is headquartered in Copenhagen, Denmark and
has US headquarters in New York, New York.
For further information, please visit
www.iobiotech.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding the timing of the interim analysis of our Phase 3 trial,
current or future clinical trials, their progress, enrollment or
results, or the company’s financial position or cash runway, are
based on IO Biotech’s current assumptions and expectations of
future events and trends, which affect or may affect its business,
strategy, operations or financial performance, and actual results
and other events may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Contact:Maryann Cimino, Director of Investor
Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From Apr 2024 to May 2024
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From May 2023 to May 2024